Danube AG

Equities

DSFIR

CH1216478797

Consumer Goods Conglomerates

End-of-day quote Euronext Amsterdam 18:00:00 2024-05-16 EDT 5-day change 1st Jan Change
107.4 CHF +0.09% Intraday chart for Danube AG +4.22% +16.79%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Dsm-Firmenich Ag Approves Retirement of Pradeep Pant from the Board CI
Dsm-Firmenich Ag Approves the Dividend, Payable May 16, 2024 CI
Global markets live: Etsy, Qualcomm, Carvana, Rio Tinto, Apple... Our Logo
DSM-FIRMENICH : Vitamin trouble is going to fade Alphavalue
U.S. Futures Up, European Stocks Mixed in Wake of Fed Remarks DJ
Transcript : DSM-Firmenich AG, Q1 2024 Sales/ Trading Statement Call, May 02, 2024
U.S. Futures Down, European Stocks Mixed DJ
DSM-Firmenich AG announces an Equity Buyback for 1,500,000 shares, representing 0.6% of its issued share capital. CI
DSM-Firmenich AG authorizes a Buyback Plan. CI
DSM-FIRMENICH : A stronger long-term outlook Alphavalue
Quiz sales fall, names new CEO; Byotrol eyes AIM exit AN
Quotes from Dutch companies on the worsening business climate RE
ASML's threat to leave uncovers deeper concerns in Netherlands Inc. RE
DSM-Firmenich Completes Sale of Vitamin C Plant in China MT
Jingjiang Cosfocus Health Technology Co., Ltd. acquired DSM Jiangshan Pharmaceutical Co., Ltd from DSM-Firmenich AG. CI
Philips: Chairman to seek second term CF
DSM-FIRMENICH : Some mess from the combination Alphavalue
Global markets live: Airbus, Cisco, BAE, Salesforce, Deere... Our Logo
FTSE 100 Closes Up As Investors Shrug Off Recession Confirmation DJ
DSM-FIRMENICH : An even pure(er) play Alphavalue
DSM-Firmenich Plans to Spinoff Pet Care Business CI
Dsm-firmenich Plans Pharmacokinetic Trial for New Cannabidiol Formulation With Zerion Pharma MT
Transcript : DSM-Firmenich AG, 2023 Earnings Call, Feb 15, 2024
Dsm-firmenich to Carve Out Animal Nutrition Business MT
DSM Firmenich plans to separate animal nutrition and health unit RE
Chart Danube AG
More charts
DSM-Firmenich AG is a leading innovator in nutrition, health, and beauty. It reinvents, manufactures, and combines vital nutrients, flavors, and fragrances for the world's growing population to thrive. With a comprehensive range of natural and renewable ingredients and renowned science and technology capabilities, the company uniquely works to create what is essential for life, desirable for consumers, and more sustainable for the planet.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
107.4 EUR
Average target price
119.8 EUR
Spread / Average Target
+11.46%
Consensus
  1. Stock Market
  2. Equities
  3. DSFIR Stock
  4. News Danube AG
  5. Dsm-firmenich Plans Pharmacokinetic Trial for New Cannabidiol Formulation With Zerion Pharma
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW